

**Associate Editors** **ix**

**Contributors** **xi**

## **Optimal Surgical Treatment for Type 2 Diabetes: Sleeve Gastrectomy or Gastric Bypass?**

Amanda Mueller, Sarah Palilla, and Jonathan Carter

Introduction	1
Clinical evidence from randomized, controlled trials	2
The physiology of obesity as it relates to diabetes	3
Mechanisms of diabetes resolution after sleeve gastrectomy or gastric bypass	4
Ghrelin	4
PYY3-36	5
Incretins	5
Bile acids and gut microbiome	5
Duodenal bypass	6
Summary	6
Disclosure	7

## **Advances in the Diagnosis and Management of Appendicitis in Children**

Katherine He and Shawn J. Rangel

Introduction	9
Relevance and approach to severity classification	10
Diagnostic evaluation	10
Diagnostic utility of clinical prediction rules and clinical scoring systems	11
Strategies to optimize the diagnostic quality of US	13
Strategies to leverage the combined predictive value of US, laboratory and clinical data	13
Role of standardized diagnostic clinical pathways	13
Surgical management	16
Influence of operative timing on outcomes and resource utilization	16
Operative approach	16
Initial medical versus operative management for complicated appendicitis	16
Role of irrigation and drains	18
Antibiotic management of uncomplicated appendicitis	18

Antibiotic management for complicated appendicitis	19
Screening and management of OSIs	20
Role of parenteral nutrition	21
Indications and timing of interval appendectomy for complicated appendicitis	21
Same-day discharge for patients with uncomplicated appendicitis	22
Approach to perioperative pain management	22
Medical management as definitive treatment for early appendicitis	22
Outcome, process, and resource utilization benchmarks	27
Future directions and priorities	27
Clinics care points	29
Disclosure	29

### **Malignant Bowel Obstruction**

Nadege T. Fackche and Fabian M. Johnston

Introduction	35
Epidemiology and pathophysiology	36
Evaluation of the patient with malignant bowel obstruction	36
Management	38
Medical therapy	38
Interventional palliation	41
Surgical Palliation	42
Summary	43
Clinics care points	44
Disclosure	44

### **Nonoperative Treatment of Diverticulitis**

Matthew Symer and Heather L. Yeo

Introduction	49
Epidemiology	50
Diverticulitis recurrence	51
Advantages of the nonoperative approach	51
Uncomplicated diverticulitis	52
Complicated diverticulitis	52
Symptomatic uncomplicated diverticular disease and chronic abdominal pain	53
Need for endoscopic examination	53
Summary	53
Clinics care points	54

### **The Current Management of Visceral Artery Aneurysms**

Bara Zuhaili and James H. Black III

Background	57
Anatomic distribution	57
Causes	58
Clinical presentation	58
Nonruptured visceral artery aneurysm	58

Ruptured visceral artery aneurysm	58
Physical examination	58
Work-up	58
Medical treatment	59
Interventional treatment	59
Indication for intervention	59
Intervention options	59
Surgical and endovascular techniques	60
Splenic artery aneurysm	60
Hepatic artery aneurysm	62
Superior mesenteric artery aneurysm	63
Pancreaticoduodenal and gastroduodenal artery aneurysms	64
Gastric/gastroepiploic artery aneurysms	66
Jejunal, ileal, and colic artery aneurysms	66
Renal artery aneurysms	67
Complications/long-term outcomes	68
Long-term recommendations	70
New developments	70
Clinics care points	71

## **Mesenteric Ischemia: When and How to Revascularize**

Kristofor A. Olson and Pedro G. Teixeira

Introduction	75
Anatomy	76
Acute mesenteric ischemia	76
Epidemiology	76
Pathogenesis	76
Clinical presentation	77
Management of acute thrombotic or embolic mesenteric ischemia	77
Management of mesenteric venous thrombosis	82
Medical management	82
Indications for interventions	82
Open surgical versus endovascular	82
Management of non-occlusive mesenteric ischemia	82
Chronic mesenteric ischemia	83
Epidemiology and pathogenesis	83
Clinical presentation	83
Medical management	83
Indications for interventions	83
Surgical versus endovascular	83
Postoperative care	84
Long-term follow-up	85
Summary	85
Clinics care points	85

## **Watch-and-wait Management for Rectal Cancer After Clinical Complete Response to Neoadjuvant Therapy**

Jonathan B. Yuval and Julio Garcia-Aguilar

Introduction	90
Terminology	91
History of watch and wait	91
Patient perspectives on watch and wait	92
Patient evaluation	92
Work-up	92
Selection of patients based on tumor stage	92
Selection of patients based on tumor location	93
Baseline characteristics associated with response to neoadjuvant therapy	93
Radiotherapy regimens	93
Enhancing the response to neoadjuvant therapy	94
Interval to assessment	94
Radiation dose	95
Addition of neoadjuvant systemic chemotherapy	95
Induction versus consolidation chemotherapy in total neoadjuvant therapy	96
Complications of neoadjuvant therapy	96
Assessment of response	97
Long-term monitoring of response	97
Long-term outcomes	97
Oncological outcomes	97
Rates of organ preservation	100
Functional outcomes	100
Summary, discussion, and future directions	103
Clinics care points	104
Disclosure	104
Financial support	104

## **Paraesophageal Hernia: Current Management**

Laura Mazer and Dana A. Telem

Introduction	109
Presentation	110
Diagnosis	111
Indications for repair	112
Management of acute presentation	113
Surgical repair	114
Need for esophageal lengthening procedure	118
Need for gastropexy	119
Summary	119
Disclosure	119

## **Surgery During a Pandemic: Guidelines**

Cole S. Brown and Andrew M. Cameron

Introduction: COVID-19's impact on health care systems: shutdown of elective procedures	123
After the shutdown: guidelines for ramping back up safely	124
Overview	124
Priorities	124

Acuity	125
Supplies	126
Capacity	126
An unpredictable pandemic: guidelines for ramping back down as needed	127
Guidelines on other important considerations	128
Patient placement and bed management	128
Infection prevention obligations and social distancing	128
Patient and visitor flow	129
Preoperative screening	129
Staff safety and well-being	129
Summary on guidelines for surgery in the time of pandemic	130
Disclosure	130

## **The Role of Node Dissection for Thyroid Cancer**

Reese W. Randle and Susan C. Pitt

Background	131
Epidemiology	132
Patient evaluation overview	132
Initial evaluation	132
Evaluation for recurrence	132
Lymph node imaging	133
Functional imaging	134
Lymph node biopsy	134
Treatment options	134
Central neck dissection	136
Lateral neck dissection	137
Reoperative neck dissection	139
Evaluation of outcomes	139
Complications	139
Completeness of resection	140
Recurrence	141
Survival	141
Long-term recommendations	141
Surveillance	141
Adjuvant RAI	141
Summary	141
Future directions	142
Clinics care points	142
Disclosure	142

## **Multimodal Pain Control in Surgery 2020**

Hannah Decker, Christopher L. Wu, and Elizabeth Wick

Introduction	147
Discussion	149
Nonsteroidal anti-inflammatory agents	149
Acetaminophen	150
Gabapentinoids	150
N-methyl-D-aspartate antagonists	151

Local anesthetics	152
Regional anesthesia/analgesia	153
Summary	153
Clinics care points	154
Disclosure	154

## **What is the Current Role of Hyperthermic Intraoperative Chemotherapy in Colorectal Cancer?**

Catherine H. Davis and H. Richard Alexander Jr.

Clinical background	159
Cytoreductive surgery and hyperthermic intraoperative chemotherapy technique	160
Historical perspective: survival after cytoreductive surgery and hyperthermic intraoperative chemotherapy for patients with colorectal cancer peritoneal metastasis	161
Toxicity and morbidity associated with cytoreductive surgery and hyperthermic intraoperative chemotherapy	163
Current status of cytoreductive surgery and hyperthermic intraoperative chemotherapy in colorectal cancer peritoneal metastasis	167
Mitomycin C versus oxaliplatin	167
Use of systemic chemotherapy with cytoreductive surgery and hyperthermic intraoperative chemotherapy	168
Cytoreductive surgery and hyperthermic intraoperative chemotherapy versus cytoreductive surgery alone	169
Hyperthermic intraoperative chemotherapy as prophylactic therapy	170
Summary	170
Clinics care points	171
Disclosure	171

## **Machine Perfusion in Liver Transplantation**

Malcolm MacConmara and Parsia A. Vagefi

 Video content accompanies this article at <http://www.advancesurgery.com>

Introduction	175
History of organ preservation	176
Early experimental work with machine perfusion	176
Contemporary advances in machine perfusion	177
Types of machine perfusion of the liver	177
Hypothermic perfusion	177
Normothermic machine perfusion	178
Advantages of machine perfusion	178
Technique of machine perfusion	178
Preparation for perfusion	178
Assessment of donor organs	179
Clinical trials	179
Hypothermic machine perfusion	179
Normothermic machine perfusion	182

Current status of clinical practice in the United States	185
Trends in normothermic machine perfusion application	185
Normothermic machine perfusion of marginal organs	186
Cost and organ allocation	186
Biomarkers	186
Current biomarkers	186
Novel biomarkers	187
Composite viability scores	187
Future advances	188
Expanding marginal livers	188
Enhancing livers	189
Integration with other novel technologies	190
Summary	191
Clinics care points	191
Conflicts of interest	191
Supplementary data	191

## **What Is the Proper Technique for Primary Laparotomy Closure?**

Charlotte Horne and Eric Pauli

Introduction	197
What layer(s) should be closed?	198
How should the linea alba be sutured?	199
Proper fascial closure technique	207
Closure adjuncts	209
Summary and recommendations	211
Clinics care points	211
Disclosure	212

## **Can Pancreatic Organoids Help in the Treatment of Pancreatic Cancer?**

Toni T. Seppälä and Richard A. Burkhart

 Video content accompanies this article at <http://www.advancesurgery.com>

Introduction	215
Nature of the problem	216
Significance (in depth analysis)	216
What biomarkers predict treatment response?	216
What is an organoid?	218
Capacity to model human disease	219
How to make use of the pure ductal cancer cell population?	220
Success rates in organoid establishment protocols	222
How are pancreatic ductal adenocarcinoma organoids used currently in research?	223
Proposed frameworks of care	225
Barriers to clinical implementation today and strategies for the future	226
Summary	227

Clinics care points	227
Disclosure	227
Supplementary material	227

## **Necrosectomy in the Management of Necrotizing Pancreatitis**

Amy Y. Li, John R. Bergquist, and Brendan C. Visser

Video content accompanies this article at <http://www.advancesurgery.com>

Introduction	232
Background and definitions	232
Indications and timing for necrosectomy	233
Approaches to necrosectomy	235
Open necrosectomy	236
Laparoscopic necrosectomy	237
Retroperitoneal debridement	238
Endoscopic transgastric drainage and necrosectomy	240
Surgical transgastric necrosectomy	242
Percutaneous drainage	245
Summary	245
Clinics care points	246
Acknowledgments	246
Supplementary data	246

## **Vascular Reconstructions for Traumatic Injuries**

Ali Khalifeh and Todd E. Rasmussen

Introduction	251
Diagnosis and initial management	252
Mechanism of Injuries and Diagnosis	252
Operating Room and Setup	255
Temporary Vascular Shunts	256
Endovascular Balloon Occlusion of The Aorta	257
Other Types of Balloon Occlusion	258
Endovascular Repair of Vascular Trauma	258
Conduits for Vascular Reconstruction	259
Anticoagulation and Antiplatelet Use	262
Anatomic regions	262
Extremity injuries	262
Cervical	264
Torso	266
Summary	269
Clinics care points	269

## **Evolution of Point-Of-Care Ultrasound in Surgical Management**

William A. Teeter and Thomas Scalea

Focused assessment with sonography for trauma	273
---	-----



Patient placement	274
Evaluation of the heart and pericardium	275
Subxiphoid view	275
Parasternal long view	276
Morison's pouch	276
Splenorenal recess	277
Pouch of Douglas	277
Thoracic views	278
Cardiac ultrasound	280
Parasternal long view	280
Parasternal short view	284
Apical four-chamber and five-chamber views	287
Assessment of hypovolemia using cardiac ultrasound	288
Intravascular catheter placement	289
Summary	294
Clinics care points: fast	295
Disclosure	295

## **Breast Implant–Associated Anaplastic Large Cell Lymphoma**

Melissa Camp

Introduction	299
Background	300
Epidemiology	300
Presentation	301
Diagnosis and workup	301
Treatment	302
Staging	303
Food and Drug Administration warnings on implants	303
Management of patients who currently have implants	303
Summary/Conclusions	304
Clinics care points	305
Disclosure	305